Next-Generation Immunosequencing Reveals Pathological T-Cell Architecture in Autoimmune Hepatitis.

Autor: Schultheiß C; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany., Simnica D; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany., Willscher E; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany., Oberle A; Department of Oncology and Hematology, BMT with Section of Pneumology, Hubertus Wad Tumorzentrum, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Fanchi L; ENPICOM B.V., 's-Hertogenbosch, the Netherlands., Bonzanni N; ENPICOM B.V., 's-Hertogenbosch, the Netherlands., Wildner NH; First Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Schulze Zur Wiesch J; First Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Weiler-Normann C; First Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Lohse AW; First Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Binder M; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.

Publikováno v: Hepatology (Baltimore, Md.) [Hepatology] 2021 Apr; Vol. 73 (4), pp. 1436-1448. Date of Electronic Publication: 2021 Feb 08.

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

Autor: Klarenbeek S; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Doornebal CW; Oncode Institute, Utrecht, The Netherlands.; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Anesthesiology, Amsterdam UMC, Amsterdam, The Netherlands., Kas SM; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Bonzanni N; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; ENPICOM, 's-Hertogenbosch, The Netherlands., Bhin J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Braumuller TM; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van der Heijden I; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Opdam M; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schouten PC; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kersten K; Oncode Institute, Utrecht, The Netherlands.; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Bruijn R; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Zingg D; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Yemelyanenko J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Wessels LFA; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of EEMCS, Delft University of Technology, Delft, The Netherlands., de Visser KE; Oncode Institute, Utrecht, The Netherlands.; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.

Publikováno v: Oncoimmunology [Oncoimmunology] 2020 Feb 12; Vol. 9 (1), pp. 1724049. Date of Electronic Publication: 2020 Feb 12 (Print Publication: 2020).

Detection of disease-specific signatures in B cell repertoires of lymphomas using machine learning.

Autor: Schmidt-Barbo, Paul^1,2 (AUTHOR), Kalweit, Gabriel^2,3 (AUTHOR), Naouar, Mehdi^2,3 (AUTHOR), Paschold, Lisa⁴ (AUTHOR), Willscher, Edith⁴ (AUTHOR), Schultheiß, Christoph¹ (AUTHOR), Märkl, Bruno⁵ (AUTHOR), Dirnhofer, Stefan⁶ (AUTHOR), Tzankov, Alexandar⁶ (AUTHOR), Binder, Mascha^1,2,7 (AUTHOR) mascha.binder@unibas.ch, Kalweit, Maria^2,3 (AUTHOR)

Publikováno v: PLoS Computational Biology. 7/2/2024, Vol. 20 Issue 7, p1-17. 17p.

Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.

Autor: Mährle T; Department of Oncology and Hematology, BMT with Pneumology section, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Akyüz N; Department of Oncology and Hematology, BMT with Pneumology section, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Fuchs P; ENPICOM, 's-Hertogenbosch, the Netherlands., Bonzanni N; ENPICOM, 's-Hertogenbosch, the Netherlands., Simnica D; Department of Oncology and Hematology, BMT with Pneumology section, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Department of Hematology and Oncology, University Hospital Halle (Saale), Germany., Germing U; Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University Düsseldorf, Germany., Asemissen AM; Department of Oncology and Hematology, BMT with Pneumology section, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Jann JC; Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany., Nolte F; Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany., Hofmann WK; Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany., Nowak D; Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany., Binder M; Department of Oncology and Hematology, BMT with Pneumology section, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany mascha.binder@uk-halle.de.; Department of Hematology and Oncology, University Hospital Halle (Saale), Germany.

Publikováno v: Haematologica [Haematologica] 2019 Jul; Vol. 104 (7), pp. 1355-1364. Date of Electronic Publication: 2019 Jan 17.

A neural network-based model framework for cell-fate decisions and development.

Autor: Paczkó, Mátyás^1,2 (AUTHOR), Vörös, Dániel^1,2 (AUTHOR), Szabó, Péter¹ (AUTHOR), Jékely, Gáspár³ (AUTHOR), Szathmáry, Eörs^1,4,5 (AUTHOR) szathmary.eors@ecolres.hu, Szilágyi, András¹ (AUTHOR)

Publikováno v: Communications Biology. 3/14/2024, Vol. 7 Issue 1, p1-13. 13p.